Sandoz Drops Counterclaims After $39M Patent Trial Loss
Generic drug giant Sandoz Inc. has decided not to pursue its antitrust counterclaims against brand-name drug company Allergan, at least for now, after a federal jury in Colorado awarded $39 million...To view the full article, register now.
Already a subscriber? Click here to view full article